This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 3-9 March 2024 and includes updates on SARS-CoV-2 variant classification, sexually transmitted infections, Psittacosis cases, product safety recall of InterPharma Sodium Chloride 0.9% 30ml linked to Ralstonia pickettii contamination, cholera and Middle East respiratory syndrome coronavirus (MERS-CoV).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the […]
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].